Simaravibart

司雷韦拜单抗

Report date: 2024/11/24 20:00:04

Base Information

Drug NameSimaravibart
Drug Alias NameMAD-0004J08
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionCoronavirus spike glycoprotein inhibitors
TargetsCoronavirus spike glycoprotein
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryItaly
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesFondazione Toscana Life Sciences
China Registration ClassN/A

Develop Information

Active CompaniesFondazione Toscana Life Sciences
Inactive CompaniesToscana Life Sciences Sviluppo srl
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A